Public Sector Pension Investment Board Grows Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

Public Sector Pension Investment Board grew its position in Vir Biotechnology, Inc. (NASDAQ:VIR) by 7.2% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 191,608 shares of the company’s stock after buying an additional 12,949 shares during the quarter. Public Sector Pension Investment Board’s holdings in Vir Biotechnology were worth $1,705,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in VIR. Vanguard Group Inc. lifted its position in shares of Vir Biotechnology by 9.8% in the fourth quarter. Vanguard Group Inc. now owns 12,297,139 shares of the company’s stock valued at $123,709,000 after acquiring an additional 1,096,473 shares in the last quarter. Federated Hermes Inc. lifted its position in shares of Vir Biotechnology by 19,327.1% in the second quarter. Federated Hermes Inc. now owns 300,148 shares of the company’s stock valued at $2,671,000 after acquiring an additional 298,603 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Vir Biotechnology by 58.7% in the first quarter. Nordea Investment Management AB now owns 235,664 shares of the company’s stock valued at $2,408,000 after acquiring an additional 87,190 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Vir Biotechnology by 10.1% in the second quarter. Dimensional Fund Advisors LP now owns 637,486 shares of the company’s stock valued at $5,673,000 after acquiring an additional 58,360 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Vir Biotechnology in the second quarter valued at approximately $431,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Insider Buying and Selling at Vir Biotechnology

In other Vir Biotechnology news, Director Janet Napolitano sold 12,190 shares of Vir Biotechnology stock in a transaction on Monday, September 9th. The stock was sold at an average price of $7.80, for a total value of $95,082.00. Following the sale, the director now owns 11,616 shares in the company, valued at $90,604.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 15.60% of the company’s stock.

Vir Biotechnology Stock Down 0.5 %

NASDAQ:VIR opened at $7.49 on Tuesday. Vir Biotechnology, Inc. has a 52 week low of $7.20 and a 52 week high of $13.09. The company has a market capitalization of $1.02 billion, a P/E ratio of -1.87 and a beta of 0.46. The stock’s fifty day moving average is $8.50 and its two-hundred day moving average is $9.22.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Thursday, August 1st. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.13). Vir Biotechnology had a negative net margin of 612.40% and a negative return on equity of 30.93%. The business had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $7.53 million. During the same quarter in the prior year, the firm earned ($1.45) EPS. Vir Biotechnology’s revenue for the quarter was down 19.0% compared to the same quarter last year. Sell-side analysts anticipate that Vir Biotechnology, Inc. will post -3.26 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research report on Tuesday, August 20th. Needham & Company LLC lifted their price objective on Vir Biotechnology from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, June 5th. Barclays lifted their price objective on Vir Biotechnology from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Finally, Morgan Stanley lifted their price objective on Vir Biotechnology from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Thursday, June 6th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $36.80.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).